CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab (Keytruda) Immunotherapy in Patients With Advanced or Metastatic Refractory Stomach and Esophageal Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06532799
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:08.183591+00:00
Published At: 2024-11-12T00:00:00+00:00
Record Updated At: 2024-11-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Stomach Cancer", "Stomach Cancer Recurrent", "Stomach Cancer, Adenocarcinoma", "Esophageal Cancer", "Esophageal Cancer Metastatic to Bone", "Esophageal Cancer Metastatic to Lung", "Esophageal Cancer Metastatic to Liver"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-11-12"
protocolSection.identificationModule.nctId: "NCT06532799"
protocolSection.identificationModule.officialTitle: "Efficacy and Safety of Autologous Tumor-Infiltrating Lymphocytes (TIL) Therapy Combined With Pembrolizumab (Keytruda) Immunotherapy in Patients With Advanced or Metastatic Refractory Stomach and Esophageal Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.